Recent Updates — CUE
Cue Biopharma announced positive topline results from a Phase 2 clinical trial of CUE-221 in patients with moderate-to-severe chronic spontaneous urticaria (CSU). The study enrolled 145 participants and compared subcutaneous doses of CUE-221 against placebo and omalizumab. At week 12, the primary endpoint of complete hives resolution (HSS7=0) was met at all dose levels, with rates of 54% for 4 mg/kg, 53% for 2 mg/kg, and 43% for 1 mg/kg versus 11% for placebo. The key secondary endpoint of complete response (UAS7=0) achieved statistical significance only at the highest dose level (46% vs 11%). Efficacy persisted through week 28, with the 4 mg/kg group showing a statistically significant advantage over omalizumab (60% vs 24%) after treatment cessation. The drug demonstrated a favorable safety profile with no treatment-related serious adverse events or anaphylaxis. Based on these findings, the company plans to initiate a Phase 2b/3 trial in CSU and a Phase 2 trial in food allergy. Cue Biopharma is a clinical-stage biopharmaceutical company developing transformative therapies for immune-mediated diseases.
Cue Biopharma reported a net loss of $153.1 million for the quarter ended June 30, 2026, driven by one-time non-cash losses and expenses related to its license agreement with Ascendant. Revenue increased to $7.9 million from collaboration milestones. The company completed a $50 million private placement financing subsequent to the quarter end to support clinical development. Key operational highlights include an IND submission for CUE-221 in food allergies, anticipated Phase 2 data readout by late Q3 2026, and leadership additions including new CMO Dr. Dominic Borie and CFO James M. Ahlers. Cue Biopharma is a clinical-stage biopharmaceutical company developing therapies for immune-mediated diseases.
Cue Biopharma appointed James Ahlers as its new Chief Financial Officer, effective July 30, 2026. The executive employment agreement provides an annualized base salary of $450,000 and a discretionary bonus target of up to 45% of base salary. Upon appointment, Mr. Ahlers received an initial grant of nonstatutory stock options for 51,000 shares at an exercise price of $30.40 per share and restricted stock units for 25,500 shares, both vesting quarterly over four years. The agreement includes severance provisions equal to nine months of base salary plus target bonus in the event of a qualifying termination. Cue Biopharma operates in the biotechnology industry, focusing on drug discovery and development.
Cue Biopharma, Inc. entered into a Securities Purchase Agreement on July 9, 2026, to issue and sell 1,418,071 shares of common stock at $33.21 per share and 87,500 pre-funded warrants at $33.209 per warrant for gross proceeds of approximately $50.0 million. The company intends to use the net proceeds to fund clinical development and general corporate purposes. Cue Biopharma, Inc. is a biopharmaceutical company focused on developing clinical-stage product candidates.